UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 14 von 567
Datensatz exportieren als...
BibTeX
Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients
Pediatric pulmonology, 2017-02, Vol.52 (2), p.190-197
Nové‐Josserand, Raphaële
Grard, Soazic
Auzou, Lila
Reix, Philippe
Murris‐Espin, Marlène
Brémont, François
Mammar, Benyebka
Mely, Laurent
Hubert, Dominique
Durieu, Isabelle
Burgel, Pierre‐Régis
2017
Details
Autor(en) / Beteiligte
Nové‐Josserand, Raphaële
Grard, Soazic
Auzou, Lila
Reix, Philippe
Murris‐Espin, Marlène
Brémont, François
Mammar, Benyebka
Mely, Laurent
Hubert, Dominique
Durieu, Isabelle
Burgel, Pierre‐Régis
Titel
Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients
Ist Teil von
Pediatric pulmonology, 2017-02, Vol.52 (2), p.190-197
Ort / Verlag
United States: Wiley Subscription Services, Inc
Erscheinungsjahr
2017
Link zum Volltext
Quelle
MEDLINE
Beschreibungen/Notizen
Summary Allergic bronchopulmonary aspergillosis (ABPA) affects up to 15% of patients with cystic fibrosis (CF). Corticosteroids are used as first‐line therapy, but relapse and adverse effects commonly occur. Case reports have suggested the efficacy of the anti‐IgE recombinant humanized monoclonal antibody omalizumab. A retrospective multicenter observational French study retrieved 32 CF patients (11 children and 21 adults) who have received omalizumab for more than 3 months in the context of ABPA. Clinical characteristics, concomitant medications (inhaled and oral corticosteroids, antifungal drugs), lung function, body mass index (BMI), and serum IgE were compared at the start and during the first year of omalizumab therapy. Omalizumab‐related adverse effects and costs were also evaluated. No significant difference with omalizumab could be demonstrated with regard to lung function, BMI, or the number of patients receiving oral corticosteroids. At the time of initiation of omalizumab, 56% of patients were receiving oral corticosteroids. Five patients were able to discontinue corticosteroids during follow‐up and nine patients were able to reduce their daily dose. A total of 78% of the patients had received antifungal therapy at the time of the initiation of omalizumab. Treatment tolerance was good (12.5% of patients experienced side effects). The median cost of omalizumab treatment was €3,620 per patient per month. Omalizumab may represent a steroid‐sparing therapy in CF patients with ABPA. A randomized‐controlled trial is urgently required to provide higher level of evidence regarding the efficacy and cost‐effectiveness of omalizumab in CF patients with ABPA. Pediatr Pulmonol. 2017;52:190–197. © 2016 Wiley Periodicals, Inc.
Sprache
Englisch
Identifikatoren
ISSN: 8755-6863
eISSN: 1099-0496
DOI: 10.1002/ppul.23612
Titel-ID: cdi_proquest_miscellaneous_1835391644
Format
–
Schlagworte
Adolescent
,
Adrenal Cortex Hormones - therapeutic use
,
Adult
,
allergic bronchopulmonary aspergillosis (ABPA)
,
Anti-Allergic Agents - therapeutic use
,
Antifungal Agents - therapeutic use
,
Aspergillosis, Allergic Bronchopulmonary - complications
,
Aspergillosis, Allergic Bronchopulmonary - drug therapy
,
Aspergillosis, Allergic Bronchopulmonary - immunology
,
Aspergillus fumigatus
,
Child
,
corticosteroids
,
cystic fibrosis
,
Cystic Fibrosis - complications
,
Drug Therapy, Combination
,
Female
,
Humans
,
IgE
,
immunoglobulin E
,
Immunoglobulin E - immunology
,
Male
,
Middle Aged
,
Omalizumab - therapeutic use
,
Retrospective Studies
,
Young Adult
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX